Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab before chemoradiation in high-risk HPV-driven oropharyngeal cancer
2018-000626-60Phase 2Completed
- Sponsor
- Unicancer
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Unicancer. Primary endpoint: Feasibility of neoadjuvant nivolumab. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2018-000626-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000626-60.